SCHEMBL23328296

SCHEMBL23328296

C=CC(=O)N1CCC(S(=O)(=O)CCCC(C)(C)C)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEAD1 P28347 6/20 0.36
TEAD3 Q99594 2/20 0.36
JAK3 P52333 8/20 0.33
THRA P10827 1/20 0.31
THRB P10828 1/20 0.31
JAK2 O60674 3/20 0.31
JAK1 P23458 3/20 0.31
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
ALDH1A1 P00352 1/20 0.30
ATM Q13315 1/20 0.30
CCNT1 O60563 1/20 0.30
CDK2 P24941 1/20 0.30
CDK7 P50613 1/20 0.30
CDK9 P50750 1/20 0.30
CCNH P51946 1/20 0.30
MNAT1 P51948 1/20 0.30
CCNA1 P78396 1/20 0.30
TET3 O43151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23328272 0.79 TEAD1 (0.49) TEAD1TEAD3JAK3THRATHRB
SCHEMBL23328572 0.73 FGFR1 (0.38) TEAD1TEAD3JAK3
SCHEMBL23328270 0.72 TEAD3 (0.47) TEAD3KMT2A
SCHEMBL23328751 0.71 TEAD1 (0.45) TEAD1TEAD3JAK3THRATHRB
SCHEMBL18904847 0.71 THRA (0.54) TEAD1TEAD3JAK3THRATHRB
SCHEMBL27437285 0.71 ALOX5AP (0.31)
SCHEMBL16030874 0.68 TEAD1 (0.56) TEAD1TEAD3JAK3JAK2JAK1
SCHEMBL15472503 0.68 CYP2D6 (0.53) TEAD1TEAD3JAK3LMNAGAA
SCHEMBL23328749 0.68 FGFR1 (0.35) TEAD1TEAD3THRATHRBKMT2A
SCHEMBL23328297 0.67 THRA (0.33) TEAD1TEAD3JAK3THRATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365196-B2 FGFR inhibitor and application thereof BETTA PHARMACEUTICALS CO., LTD. (CN) 2022-06-21 US disclosed
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF BETTA PHARMACEUTICALS CO., LTD. (CN) 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11365196-B2 FGFR inhibitor and application thereof FGFR1, FGFR4, FGFR2 TEAD1 1181/4885TEAD3 1649/4885JAK3 196/4885
US-20210130353-A1 FGFR INHIBITOR AND APPLICATION THEREOF FGFR1, FGFR4, FGFR2 TEAD1 1176/4885TEAD3 1580/4885JAK3 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.